metaPreg - Vigabatrin (All indications) during pregnancy

Vigabatrin (All indications)

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	5.04 [1.16, 21.81]	0%	5 studies	49,587	20	serious	ROB	9.55 [1.60; .]
Major congenital malformations	5.04 [1.16, 21.81]	0%	5 studies	49,587	20	serious	ROB	9.55 [1.60; .]
Congenital heart defects	12.98 [0.62, 271.33]	-	1 study	4	6	not evaluable	ROB	-
Digestive system anomalies	16.71 [0.77, 363.61]	-	1 study	3	6	not evaluable	ROB	-
Hypospadias	8.96 [0.45, 179.29]	-	1 study	6	6	not evaluable	ROB	-
Limb defects	23.44 [1.00, 547.07]	-	1 study	2	6	not evaluable	ROB	46.37 [1.07; .]
Neural Tube Defects	39.12 [1.43, 1070.14]	-	1 study	1	6	not evaluable	ROB	77.74 [2.21; .]
Oro-facial clefts	39.12 [1.43, 1070.14]	-	1 study	1	6	not evaluable	ROB	77.74 [2.21; .]
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Low birth weight (< 2500g)	1.68 [0.22, 12.99]	-	1 study	250	13	not evaluable	ROB	-
Preterm (< 37 weeks)	0.51 [0.03, 8.67]	-	1 study	383	13	not evaluable	ROB	-
Small for gestational age (weight)	0.66 [0.09, 5.06]	-	1 study	595	13	not evaluable	ROB	-
Hide endpoints reported in only one study ...